Development of Artificial Antigen Presenting Cells for Prostate Cancer Immunotherapy
Annual rept. 1 May 2003-30 Apr 2004
JOHNS HOPKINS UNIV BALTIMORE MD
Pagination or Media Count:
A major goal in cancer immunotherapy is to generate an effective anti-tumor immune response. Adoptive immunotherapy involves stimulation of tumor-specific T cells, ex vivo outside the body, followed by transfer of expanded numbers of activated T cells back into patients. While adoptive immunotherapy holds promise as a treatment for cancer, development of adoptive immunotherapy has been impeded by the lack of a reproducible and economically viable method for generating therapeutic numbers of antigen-specific CTL. The work proposed in this application will enable advances in adoptive immunotherapy. Most prostate cancers express prostate specific molecules. These molecules, including PSA and PMSA, can serve as potential targets for immune-based treatments. Studies on immune recognition of these molecules have already identified potential target regions within these proteins and are the basis of a variety of different experimental immunotherapies for treatment of prostate cancer. In this study we propose to study the ability to use HLA-Ig based aAPC as a viable method for induction, expansion and activation of prostate specific T cells for immunotherapy for prostate cancer. These studies will serve as precursor ones for induction and expansion of prostate specific CTL from patients with disease for initiation of adoptive immunotherapy phase I clinical studies.
- Medicine and Medical Research